While some information on these therapeutic candidates is restricted by confidentiality agreements, in the table below you will find links that offer more information about disclosed assets. We provide this information for informational purposes only.
| Marketer | Asset Name | Target | Royalty Rate | |||
|---|---|---|---|---|---|---|
| Day One | OJEMDA™ (tovorafenib) | Pan-RAF inhibitor | Mid-single-digit | clinical trials | news | posters, presentations |
| Medexus | IXINITY® | Recombinant Factor IX | Mid-single-digit | news | asset website | |
| Organon | XACIATO™ | Bacterial vaginal infection | High single-digit | news | asset website | |
| Roche | VABYSMO® (faricimab-svoa) | Angiopoietin-2 and VEGF-A bispecific antibody | 0.5% | clinical trials | news | posters, presentations |
| Talphera | DSUVIA® (sufentanil sublingual tablet) | Acute pain treatment | 37.5-75% (DoD) | clinical trials | news | asset website |
| Zevra | MIPLYFFA™ (arimoclomol) | Heat-shock protein amplifier | Mid-single-digit | clinical trials | news | asset website |
| Developer | Asset Name | Target | Royalty Rate | |||
|---|---|---|---|---|---|---|
| AstraZeneca | Rilvegostomig (AZD2936) | TIGIT/PD-1 bispecific antibody | Undisclosed | clinical trials | news | posters, presentations |
| AVEO, an LG Chem company | Ficlatuzumab (AV-299) | HGF antibody | Low-single-digit | clinical trials | news | posters, presentations |
| Castle Creek Biosciences | D-Fi (FCX-007) | Gene therapy | <1.0% | clinical trials | ||
| Chiesi & Gossamer | Seralutinib | Inhaled PDGFR, CSF1R, c-KIT inhibitor | Low to mid-single digit, net | clinical trials | news | posters, presentations |
| Daré Bioscience | Ovaprene® | Hormone-free contraceptive | Low-single-digit | clinical trials | news | posters, presentations |
| Johnson & Johnson | Cetrelimab (JNJ-63723283) | PD-1 antibody | 0.75% | clinical trials | news | posters, presentations |
| Rezolute | Ersodetug (RZ358) | INSR antibody | High-single-digit to mid-teens | clinical trials | news | posters, presentations |
| Takeda | Mezagitamab (TAK-079) | CD-38 antibody | Low-single-digit | clinical trials | news | posters, presentations |
| Developer | Asset Name | Target | Royalty Rate | |||
|---|---|---|---|---|---|---|
| Affimed | Acimtamig (AFM13) | CD30/CD16A innate cell engager | Undisclosed | clinical trials | news | posters, presentations |
| Affimed | AFM24 | EGFR/CD16A innate cell engager | Undisclosed | clinical trials | news | posters, presentations |
| Daré Bioscience | Sildenafil cream, 3.6% | PDE-5 inhibitor | Low-single-digit | clinical trials | news | posters, presentations |
| Denovo Biopharma | Vosaroxin | Topoisomerase II inhibitor | High-single-digit | clinical trials | news | posters, presentations |
| LadRx | Aldoxorubicin | Albumin-linked formulation of doxorubicin | Low-single-digit | clinical trials | news | posters, presentations |
| National Resilience | G03-52-01 | Botulinum neurotoxin antibodies | 15% | |||
| Palobiofarma | PBF-680 | Adenosine A1 receptor inhibitor | Low-single-digit | clinical trials | news | posters, presentations |
| Palobiofarma | PBF-677 | Adenosine A3 receptor inhibitor | Low-single-digit | clinical trials | news | posters, presentations |
| Regeneron | Vidutolimod (CMP-001) | Virus-like particle containing a TLR9 agonist | High-single-digit to double-digit | clinical trials | news | posters, presentations |
| Rezolute | RZ-402 | Plasma kallikrein inhibitor | Low single-digit | clinical trials | news | posters, presentations |
| Developer | Asset Name | Target | Royalty Rate | |||
|---|---|---|---|---|---|---|
| Compugen | COM902 | TIGIT antibody | Undisclosed | clinical trials | news | posters, presentations |
| Johnson & Johnson | JNJ-89853413 | Bispecific Vδ2 T-cell engager | Low-single-digit | clinical trials | news | |
| Molecular Templates | MT-0169 | Anti-CD-38 immunotoxin | 4% | clinical trials | news | posters, presentations |
| Monopar Therapeutics | MNPR-101 | Urokinase plasminogen activator receptor (uPAR) radioimmunotherapeutic | None | news | posters, presentations | |
| Palobiofarma | PBF-999 | Adenosine A2a receptor/ PDE-10 inhibitor | Low-single-digit | clinical trials | news | posters, presentations |
| Palobiofarma | PBF-1129 | Adenosine A2b receptor inhibitor | Low-single-digit | clinical trials | news | posters, presentations |
| Palobiofarma | PBF-1650 | Adenosine A3 receptor inhibitor | Low-single-digit | clinical trials | news | posters, presentations |
| Pfizer | PF-08046052 | Anti-EGFR bispecific γδ T-cell engager | Low-single-digit | clinical trials | news | |
| Rezolute | AB101 | Injectable basal insulin | Low-single-digit | news | posters, presentations | |
| Twist Bioscience's 30+ partners | 60+ early-stage assets | Multiple targets | 50% of up to low-single-digits |
All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
